Syndax Pharmaceuticals Inc to Host an Investor Call Transcript
Good day, everyone, and welcome to the Pivotal AUGMENT-101 top line Revumenib data conference call. Today's call is being recorded. At this time, I would like to turn the call over to Sharon Klahre, Head of Investor Relations at Syndax Pharmaceuticals.
Thank you, operator. Welcome, and thank you all for joining us today. I'm Sharon Klahre and with me this morning to provide a review of topline results from the Pivotal AUGMENT-101 trial of Revumenib in relapsed/refractory adult and pediatric patients with KMT2Ar, acute leukemia, are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D. Also joining us on the call today for question-and-answer session are Dr. Peter Ordentlich, Chief Scientific Officer; Dr. Anjali Ganguli, Chief Business Officer; and Keith Goldan, Chief Financial Officer.
This morning, we issued a press release and reported topline data for the Pivotal AUGMENT-101 trial of Revumenib in relapsed or refractory KMT2Ar acute
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |